Even though Bayer sweetened the pot in its attempt to win Monsanto, analysts suggest the seed company's board is likely to reject the offer. » Read More
Kevin Kelly, CIO of Recon Capital Partners, explains why he loves the German company's stock.
Chipotle Mexican Grill's new GMO-free menu claims have lured diners, but it has some consumers crying foul.
European markets finished higher on Monday following a rally in U.S. stocks as the oil price surged as much as 2 percent.
DAX all folks
European stocks finished higher on Wednesday after a bumper day of earnings, while investors awaited news from a two-day policy meeting of the U.S. Federal Reserve.
The CEO of German drugmaker Bayer has quashed any talk of acquiring its competitor Syngenta, which is being pursued by U.S. firm Monsanto.
Marijn Dekkers, CEO of Bayer, says Syngenta wouldn't be a logical acquisition target for Bayer.
European equities tumbled on Wednesday to close sharply lower as investors reacted to sharp gains in the euro against the dollar.
European equities rallied on Thursday, closing nearly 1 percent higher as investors reacted to a raft of corporate earnings and fresh economic data.
New drugs and increased spending on research and development mean the "stars are aligned" for German drugs giant Bayer, the firm's CEO said.
Marijn Dekkers, CEO of Bayer, talks about the company's plans to separate themselves from their material science unit, saying they will focus on life sciences businesses going forward.
Marijn Dekkers, CEO of Bayer, says the company plans to increase its R&D budget this year, after strong earnings.
Merck reported earnings that beat analysts' expectations, but global sales dropped amid patent expirations and a drop in sales of its hep C drugs.
European shares closed higher on Thursday after an important announcement regarding the meetings of the European Central Bank.
Germany's largest drugmaker, Bayer, plans to float its plastics business on the stock market and focus on healthcare and crop science.
Marijn Dekkers,CEO of Bayer, says now is a "good time" to float the company's plastics business and prefers the IPO route.
Merck reported better-than-expected quarterly results, with sales of newer drugs mostly offsetting declining sales of drugs facing generic competition.
The way consumers would be informed when their food has been genetically engineered is being battled in Congress and among advocacy groups.
But Merck chief Kenneth Frazier also said the government needs to modify its high corporate tax code to level the playing field for American companies.
Some of the names on the move ahead of the open.